Daiichi Sankyo Files Edoxaban For Venous Thromboembolism And Non-valvular Atrial Fibrillation In Japan
This article was originally published in PharmAsia News
Daiichi Sankyo filed an application for the additional indication of its oral anticoagulant factor Xa inhibitor Lixiana (edoxaban) for the treatment of venous thromboembolism and non-valvular atrial fibrillation in Japan.
You may also be interested in...
Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.